Exchange: OTC·Updated 03:48 PM EST

ELTP News

News
all
press releases
Elite Pharmaceuticals vs. Aytu: Which CNS Stock Is the Better Buy?
ELTP and AYTU have different CNS portfolios, growth drivers and valuations, but which pharmaceutical stock looks better positioned? Let's dive in.
Zacks
Elite Pharmaceuticals vs. Aytu: Which CNS Stock Is the Better Buy?
ELTP and AYTU have different CNS portfolios, growth drivers and valuations, but which pharmaceutical stock looks better positioned? Let's dive in.
Zacks
More News
Elite Pharmaceuticals' downgrade to Neutral cites pricing pressure, weaker revenue and margins, and limited visibility into new-product contributions.
Zacks
Elite Pharmaceuticals and Journey Medical follow different growth paths, but which looks more compelling now? Let's dive in.
Zacks
ELTP's first-quarter fiscal 2027 revenues decline as generic competition and lower pricing offset higher volumes, while pipeline development remains a growth focus.
Zacks
Generic drug tariffs could impact ELTP and CPIX.
Zacks
Elite Pharmaceuticals and Cumberland Pharmaceuticals follow different growth paths, but which looks more compelling now? Let's dive in.
Zacks
ELTP delivers record fiscal 2026 results, with stronger profits, improved cash and pipeline progress supporting its expanding generics platform.
Zacks
GE, SHEL and MCK lead Zacks picks, driven by strong demand, cash flow growth and strategic expansion despite cost and market risks.
Zacks
GE Aerospace gains on strong engine demand and defense tailwinds, while Shell and McKesson navigate mixed performance and strategic shifts.
Zacks
ELTP reports surging revenue and profit in third-quarter fiscal 2026, but margin pressure and M&A ambitions steal the spotlight.
Zacks

Advertisement|Remove ads.